SCHEMBL371275

SCHEMBL371275

CCCCCCCCC=CCCCCCCCC(=O)OC(CO)C(P)OC(=O)CCCCCCCCCCCCCCCCC

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.60
PRKCE Q02156 1/20 0.60
PRKCQ Q04759 1/20 0.60
PRKCD Q05655 1/20 0.60
MAPT P10636 2/20 0.57
CNR2 P34972 2/20 0.57
CNR1 P21554 2/20 0.57
FAAH O00519 1/20 0.57
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
DGKA P23743 1/20 0.56
MAPK1 P28482 1/20 0.53
S1PR1 P21453 1/20 0.52
DAGLA Q9Y4D2 1/20 0.49
SLC6A5 Q9Y345 1/20 0.49
LPAR1 Q92633 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369084 1.00 PRKCA (0.60) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL371296 1.00 PRKCA (0.60) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL369798 1.00 PRKCA (0.60) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL26602804 1.00 PRKCA (0.60) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL369784 1.00 PRKCA (0.60) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL9958966 0.91 MAPT (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL369749 0.91 MAPT (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL367858 0.91 MAPT (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL368664 0.91 MAPT (0.62) PRKCAPRKCEPRKCQPRKCDMAPT
SCHEMBL16612104 0.90 PRKCA (0.68) PRKCAPRKCEPRKCQPRKCDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015036044-A1 CATIONIC LIPID VEHICLES FOR DELIVERY OF TLR7 AGONISTS FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD TELORMEDIX SA (CH) 2015-03-19 WO claimed
US-20150079155-A1 Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood BIONEER A/S (DK) 2015-03-19 US claimed
EP-2825158-A1 CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD Bioneer A/S (DK) 2015-01-21 EP claimed
WO-2013135800-A1 CATIONIC LIPOSOMAL DRUG DELIVERY SYSTEM FOR SPECIFIC TARGETING OF HUMAN CD14+ MONOCYTES IN WHOLE BLOOD BIONEER A/S (DK) 2013-09-19 WO claimed
EP-2638896-A1 Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood Bioneer A/S (DK) 2013-09-18 EP claimed
EP-4384612-A1 IMPROVED METHOD FOR SMALL RNA PURIFICATION Mirnagreen S.r.l. (IT) 2024-06-19 EP disclosed
CN-111867634-B Enhancement of translocation of micro/nanoparticles across mucus layers using alginate oligomers 阿尔吉法玛公司 2024-06-11 CN disclosed
CN-117940563-A Improved small RNA purification process 米尔纳格林有限责任公司 2024-04-26 CN disclosed
WO-2023017116-A1 IMPROVED METHOD FOR SMALL RNA PURIFICATION MIRNAGREEN S.R.L. (IT) 2023-02-16 WO disclosed
EP-4134432-A1 IMPROVED METHOD FOR SMALL RNA PURIFICATION Mirnagreen S.r.l. (IT) 2023-02-15 EP disclosed
CN-114729336-A Cell-free composition for ATP regeneration and use thereof 百奥堪引赛股份有限公司 2022-07-08 CN disclosed
US-20220204967-A1 METHODS FOR EXTRACTING BIOACTIVE SMALL RNAS FROM PLANTS AND MUSHROOMS MIRNAGREEN S.R.L. (IT) 2022-06-30 US disclosed
EP-2638896-A1 Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood Bioneer A/S (DK) 2013-09-18 EP disclosed
US-20130204121-A1 NANOPARTICLE-GUIDED RADIOTHERAPY TECHNICAL UNIVERSITY OF DENMARK (DK) 2013-08-08 US disclosed
EP-2593186-A1 NANOPARTICLE-GUIDED RADIOTHERAPY Technical University of Denmark (DK) 2013-05-22 EP disclosed
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES RIGSHOSPITALET (DK) 2012-08-23 US disclosed
WO-2012079582-A1 ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS TECHNICAL UNIVERSITY OF DENMARK (DK) 2012-06-21 WO disclosed
EP-2453927-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES Technical University of Denmark (DK) 2012-05-23 EP disclosed
WO-2012007567-A1 NANOPARTICLE-GUIDED RADIOTHERAPY TECHNICAL UNIVERSITY OF DENMARK (DK) 2012-01-19 WO disclosed
WO-2011006510-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES TECHNICAL UNIVERSITY OF DENMARK (DK) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120213698-A1 LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES LIPG, NPC1L1, CD47 PRKCA 3147/4885PRKCE 2962/4885PRKCQ 2109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.